echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Professor Han Baohui: Chinese data is needed for three generations of EGFR-TKI for lung cancer with ethnic differences between East and West

    Professor Han Baohui: Chinese data is needed for three generations of EGFR-TKI for lung cancer with ethnic differences between East and West

    • Last Update: 2021-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    *Only for medical professionals to read for reference.
    Three times the conventional dose of vomitinib is safe for the treatment of EGFR 20 ins mutant NSCLC in China
    .

    At the just-concluded European Medical Oncology Annual Conference (September 16th-September 21st), the third representative of the original research in China, the skin growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) mesylate The Phase Ib clinical study (FAVOUR) of metinib (hereinafter referred to as "Vometinib") for the treatment of epidermal growth factor receptor (EGFR) 20 exon insertion (ex20 ins) advanced non-small cell lung cancer (NSCLC) was announced Results of the first-line treatment cohort (Abstract #1325) [1]
    .

    FAVOUR study design [1] The results showed that 10 patients who received 240 mg of vomitinib per day first-line treatment all had different degrees of tumor target lesion reduction, with a median shrinkage of -51.
    8% and a disease control rate of 100%; The tumors of 6 patients reached the objective remission standard, and the ORR confirmed by the independent review committee was 60% [1]
    .

    The results of the FAVOUR study efficacy: all patients had different degrees of tumor target lesion reduction [1] In terms of safety, 9 patients in the group had treatment-related adverse reactions, and the most common treatment-related adverse reaction was diarrhea; 1 case was due to diarrhea The treatment was interrupted for 6 days, and then 240 mg vomitinib daily was continued; however, no adverse reactions of grade 3 or higher were observed in this cohort [1]
    .

    Although the sample size of the FAVOUR study was small, three times the conventional dose of vomitinib treatment (median drug exposure time 4.
    1 [2.
    7-5.
    4] months) did not bring about a case of ≥ grade 3 adverse reactions, and the overall suggestion of vomitinib It is a third-generation EGFR-TKI with good safety
    .

    This brings a broad clinical application space for its use in rare and rare EGFR-mutant NSCLC, lung cancer brain metastasis NSCLC, and postoperative adjuvant therapy
    .

    The results of the Phase IIa clinical study of vometinib announced at the World Lung Cancer Congress in 2020 found that the daily dose of 160 mg of vometinib was effective in treating patients with brain metastases in the brain of 84.
    6%, while the effective rate of 80 mg treatment was 60%.
    And compared to taking 80 mg daily, taking 160 mg daily did not significantly increase serious adverse reactions [2]
    .

    WCLC announced the efficacy results for patients with CNS metastases in different dose groups (data deadline: 2020-01-29) [3] In the era of EGFR-mutated advanced NSCLC gradually becoming a chronic disease, what challenges will targeted therapy face? In addition to ORR, PFS, and OS, which are the evaluation indicators of drug efficacy, what other indicators will have more clinical significance? How important is the long-term safety of the third-generation EGFR-TKI to make lung cancer a chronic disease? Recently, this platform interviewed the lead person of the FAVOUR study, Professor Han Baohui, Department of Respiratory Medicine, Shanghai Chest Hospital, Jiaotong University, and conducted in-depth communication on these issues
    .

    Professor Han Baohui’s interview video ▎Medical Tumor Channel: With the continuous iterative update of EGFR/ALK driver gene target drugs, the survival time of patients with EGFR/ALK mutation-positive advanced NSCLC is getting longer and longer
    .

    In this context, what challenges are still facing treatment? Professor Han Baohui: In the 16 years since the first EGFR-TKI drug was approved for the treatment of advanced NSCLC in China in 2005, the first, second and third generations of targeted therapies targeting EGFR targets contained Platinum chemotherapy significantly improves disease-free survival, and turning advanced lung cancer into a chronic disease has become a reality in some patients
    .

    Although targeted therapies cannot completely eliminate tumors and cure advanced lung cancer, they allow some lung cancer patients to survive with tumors
    .

    But in the process of turning lung cancer into chronic, the biggest obstacle that needs to be overcome is the metastasis of cancer cells to important organs.

    .

    Among the important organ metastases, brain metastases should be the first to bear the brunt, because nearly half of stage IV advanced non-small cell lung cancer will have different degrees or different manifestations of brain metastases, and this kind of brain metastasis will eventually constitute the greatest impact on patients.
    Existential threat
    .

    ▎Medical Cancer Channel: Does the treatment of lung cancer CNS metastasis often need to increase the dose of drugs? Professor Han Baohui: Compared with the first-generation EGFR-TKI, the third-generation EGFR-TKI can penetrate the blood-brain barrier and enter the brain better; however, in clinical practice, the treatment of brain metastases or meningeal metastasis is the same as the treatment of rare or rare EGFR mutations.
    It is often necessary to increase the dose of the drug to ensure sufficient drug concentration in the cerebrospinal fluid and brain
    .

    However, whether the dose can be increased is closely related to the safety and tolerability of the drug
    .

    The dose intensity of anti-tumor drugs is positively correlated with reducing tumor burden and achieving tumor downgrading
    .

    That is to say, within a certain limit, increasing the dose of the drug can enhance the energy efficiency of killing tumors or reducing tumor burden
    .

    The therapeutic window of chemotherapeutics is relatively narrow because it has a dose-limiting toxicity; while the therapeutic window of targeted therapies is relatively wide, which lays a safe foundation for us to overcome drug resistance and overcome the problem of metastasis of special organs
    .

    But to increase the dose of drugs, our biggest concern is the safety hazards caused by high doses
    .

    This safety hazard includes organ toxicity, such as liver failure, severe diarrhea and interstitial pneumonia
    .

    If the therapeutic effect of increasing the dose is far greater than its toxicity, especially if we increase to twice the dose, or even three times the dose, and the drug safety data is similar to the recommended dose, I think it is rare for lung cancer brain metastasis.
    Or rare EGFR-mutant NSCLC will be a very good treatment strategy
    .

    ▎Medical Tumor Channel: In the FAVOUR study, the use of three times the conventional dose (240mg) of vometinib did not cause serious adverse reactions
    .

    Why did you choose this dose? Professor Han Baohui: In the phase I dose escalation trial of vomitinib, the dose was increased from 20 mg/d to 240 mg/d.
    No dose-limiting toxicity was observed, and the maximum tolerated dose was not obtained
    .

    Among the 130 patients in the phase I dose escalation trial and the phase I-II dose expansion trial, 18 patients received 240 mg/d treatment.
    Adverse events ≥ grade 3/treatment-related adverse events did not increase compared with the 80 mg/d patient group.
    Good security
    .

    The preliminary results of the FAVOUR study showed that 240 mg vometinib treatment still has a relatively good safety record.
    Except for a relatively higher increase in diarrhea, the incidence of liver toxicity and interstitial pneumonia has not significantly increased
    .

    ▎Medical Oncology Channel: Why can the safety window of vomitinib be so wide? Professor Han Baohui: Vometinib innovatively introduces the trifluoroethoxypyridine structure, so that its prototype drug and its main metabolites have high anti-tumor activity, and their anti-tumor effects are highly selective
    .

    In fact, the other three generations of EGFR-TKIs are also very specific for the selection of EGFR mutation targets, but the metabolites after entering the human body lose high selectivity, and can inhibit EGFR sensitive mutations and EGFR wild-type.
    Will cause more adverse reactions
    .

    ▎Medical Oncology Channel: Currently, there are three third-generation EGFR-TKI drugs approved for treatment of advanced lung cancer in China
    .

    In clinical practice, if a patient is intolerant to one drug, will he consider switching to another third-generation EGFR-TKI drug? Professor Han Baohui: Multiple drugs of the first, second and third generation EGFR-TKI provide our clinicians with very good multiple options, bringing flexibility to doctors for more effective and safe treatment
    .

    For example, when a third-generation EGFR-TKI causes severe interstitial pneumonia and the drug has to be discontinued, or the patient cannot tolerate continued treatment due to severe diarrhea, we can choose other third-generation EGFR drugs
    .

    I think that vomitinib, as an excellent third-generation EGFR TKI therapeutic drug that is relatively safe and relatively low in side effects, can completely "act on its own" when the toxicity of other drugs cannot be tolerated, because it The curative effect and safety of the product have been verified in clinical research and clinical practice
    .

    ▎Medical Cancer Channel: At present, three generations of EGFR-TKI targeted drugs have been approved for the adjuvant treatment of early and mid-stage NSCLC patients in China
    .

    For postoperative adjuvant therapy, is the safety of targeted therapy drugs more important? Professor Han Baohui: The drug-assisted treatment of early and mid-stage lung cancer after R0 resection is basically an intervention without tumor burden.
    It is a preventive treatment, so the requirements for safety are much higher than that of no surgery.
    Advanced lung cancer that can only receive palliative medical treatment
    .

    In general, the course of adjuvant therapy is longer than that of advanced lung cancer
    .

    At present, although based on the results of large-scale phase III clinical studies in the world, China's drug approval and regulatory authorities have approved three-generation EGFR-TKI for postoperative adjuvant treatment of IB-IIIA stage NSCLC patients, but I think we still need to produce three-generation EGFR- TKI is used to assist the treatment of evidence-based medicine in the Chinese population to better guide our clinical practice
    .

    Because whether it is chemotherapy, targeted therapy, or the current raging immunotherapy, there are significant differences between the Caucasian race and other races, such as the Chinese population, in terms of therapeutic efficacy and safety
    .

    Therefore, although large-scale clinical studies have been done for foreign countries, if the sample size in China is not enough, I think it is absolutely necessary for our Chinese companies and Chinese experts to take the lead in conducting large-scale phase III confirmatory studies for Chinese patients.
    Clinical trials to understand the efficacy and safety of treating Chinese patients
    .

    A randomized, double-blind, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, led by He Jianxing, Dean of the First Affiliated Hospital of Guangzhou Medical University.
    The placebo-controlled, multi-center Phase III registered clinical study (FORWARD) was launched this year
    .

    The study compares the efficacy and safety of vomitinib and placebo in adjuvant treatment for 3 years
    .

    We hope that FORWARD research can fill this gap
    .

    On September 25th, during the upcoming 24th CSCO Conference, Professor Han Baohui will meet with Professor Hu Jian, Director of the Lung Disease Diagnosis and Treatment Center of the First Affiliated Hospital of Zhejiang University School of Medicine, and the Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Professor Xiaorong Dong presented the latest clinical research progress of three generations of EGFR-TKIs including vometinib for advanced and early-mid-term NSCLC
    .

    Expert profileProfessor Han Baohui, director of the Department of Respiratory Medicine, Chief Physician, and Doctoral Supervisor of Shanghai Chest Hospital, Executive Dean of China Lung Cancer Institute, Shanghai Leading Talent and Outstanding Subject Leader, Deputy Director of Shanghai Thoracic Oncology Institute, Ph.
    D.
    and Shanghai Second Medical University Postdoctoral Supervisor Director of the Drug Clinical Research Institute of Shanghai Chest Hospital, Chairman of the Oncology Branch of the Asia-Pacific Society of Medical Immunology, Chairman of the Special Allowance of the State Council, National Medical Products Administration (NMPA) Review Expert, CSCO Tumor Vascular Targeting Professional Committee, CSCO Tumor NSCLC Professional Committee Deputy Director Committee Chinese Anti-Cancer Association National Cancer Clinical Executive Committee Deputy Chairman of the Chinese Anti-Cancer Association Cancer Precision Diagnosis and Treatment Committee Member of the Standing Committee of the Respiratory Branch of the Chinese Medical Association References: [1].
    Baohui Han et al.
    , Preclinical and Preliminary Clinical Investigations of Furmonertinib in NSCLC with EGFR exon 20 insertions (20ins); 2021 ESMO, Abstract 1325[2].
    Y.
    Shi et al.
    , CNS Efficacy of AST2818 in Patients with T790M-Positive Advanced NSCLC: Data from a Phase I-II Dose-Expansion Study , 2020 WCLC, Abstract 3286*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.